Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Personalized medicine revolution is underway in Vancouver

Personalized medicine revolution is underway in Vancouver

Stories Oct 6, 2017 3 minutes

Precision medicine lab researchers to tailor genetic therapies for immune disease.

It’s being called the future of health care. Precision, or personalized, medicine based on a patient’s individual genetic profile, is revolutionizing treatment and diagnosis of disease. VCHRI Research Scientist Dr. Paul Keown and his colleagues have big plans to play a pivotal role in this genetic revolution. Their focus is on immune disease and transplantation. The team is midway through an approval process to transform the Immunology Lab at VGH into a Precision Medicine Core, which would provide sophisticated, state-of-the-art molecular testing to health researchers and patients across Canada. 

Flow cytometers that measure cell structure and function in the current Immunology Lab, slated to be transformed into the Precision Medicine Core Lab in 2018.

“This work applies advanced genomic technologies to complex immune disease. We want to understand the molecular mechanisms in each disease that cause the immune system to malfunction. We can then use that information to target specific therapies, ” says Keown.

Keown says the new technologies could transform treatment for diseases like multiple sclerosis and lupus. It could also combat immune system rejection of organ transplants.  The new lab, with DNA sequencing machinery, would focus on stem cell transplantation, solid organ transplantation (e.g., heart, lung kidney, pancreas, liver) and a range of immune disorders (e.g., rheumatoid arthritis and other inflammatory and auto-immune diseases).  

Dr. Keown is a VCHRI researcher and a professor in the Division of Nephrology at the University of British Columbia.

The team will build on its own success: the current lab was the first in Canada to implement next-generation sequencing for Human Leucocyte Antigens (HLA), the genes which regulate the immune system. This work was partly enabled by a VCHRI research grant to identify biomarkers for optimizing anti-rejection drugs for transplant patients.

We’re moving almost everything to a genetic level—looking at the specific genes that cause or aggravate organ rejection. We’ve already identified them by their sequence and now we are discussing ways to match donors and recipients at a genetic level.

Keown says doctors will one day be able to track and treat—on a cellular level, with tailor-made molecular drugs—the body’s response to transplanted organs before physiological symptoms are noted and irreversible damage happens. He says the advances have huge implications for drug therapies in all disease treatment.

“We’re asking: what are the genetics that control how each person handles drugs? Currently, we give all patients the same doses and the same medications.  Now our genetic data is telling us this is almost certainly wrong."

We are seeing up to a 10 times difference in how two individuals absorb the same drug. It’s like Goldilocks and the Three Bears. We want to get it just right for each person.

From a drop of blood to a string of DNA

When Keown was in medical school, researchers had just begun to understand the rare genetic diseases that newborn heel prick tests now screen for. “We now intervene immediately with newborns to prevent severe disability later on.  We think we will see the same opportunity with precision medicine: we will be able to take a sample at birth, sequence the DNA, and identify the diseases for which that child is at risk. Then we can act early and precisely. It’s a revolution not only in prevention, but in treatment.”

These genetic advances have profound meaning for Keown, who was the first director of the BC Transplant Society 30 years ago. Many of the disorders that create a need for organ donations—like kidney disease, which makes up the majority of transplants in BC—may have a genetic origin.

Keown hopes one day, transplant researchers like him will be out of a job, as precision technology and precision drugs find, treat and potentially cure more disease. “I’m extremely fortunate to be part of such an exciting field of study, where progress is made every day.” Keown hopes the new precision medicine lab will be operational in 2018. 

Researchers

Paul Keown

Related Articles

Discovery offers new insights to understand and treat prostate cancer

Preventative heart care leverages family connections

Honing in on precision treatments for endometriosis

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy